GE HealthCare account plan
Medical technology solutions innovator
At a glance
GE HealthCare sells imaging, ultrasound, monitoring and contrast agents in over 160 countries: $20,625 million FY2025 revenue, ~54,000 colleagues.
GE HealthCare Technologies Inc. (Nasdaq: GEHC), headquartered in Chicago and spun off from General Electric on January 3, 2023, sells medical devices, consumables, services and AI-enabled cloud and software to hospitals, health systems and researchers in over 160 countries. Its portfolio spans CT, MR, molecular imaging, X-ray, ultrasound and interventional systems, patient monitoring and anesthesia, and contrast media and radiopharmaceuticals. FY2025 total revenues were $20,625 million (+4.8% reported, +3.5% organic), with operating income of $2,763 million, net income attributable of $2,084 million and free cash flow of $1,505 million. It has approximately 54,000 colleagues, including about 9,700 sales professionals and 8,900 field service engineers, and manufactures in 44 facilities across 17 countries.
Business units
Advanced Imaging Solutions (AIS)
about 71% of Q2 2026 revenue ($3,771 million)Formed in Q2 2026 by combining Imaging and Advanced Visualization Solutions; it covers Radiology (CT, MR, molecular imaging, X-ray, women's health), Procedural Guidance and Specialized Ultrasound, and includes Intelerad imaging software. Q2 2026 revenue rose 7.9% (+5.0% organic) with segment EBIT of $525 million (13.9% margin). In FY2025 Imaging was led by Roland Rott and AVS by Philip Rackliffe.
Pharmaceutical Diagnostics (PDx)
about 14% of FY2025 revenue ($2,900 million)Contrast media for CT, X-ray, MR and ultrasound and radiopharmaceuticals for SPECT and PET in neurology, cardiology and oncology; it is the highest-margin segment. Q2 2026 revenue was $843 million (+14.6% organic) with a 29.6% EBIT margin, helped by volume and price. Led by Kevin O'Neill.
Patient Care Solutions (PCS)
about 15% of FY2025 revenue ($3,086 million)Patient monitoring, diagnostic cardiology, maternal infant care and anesthesia delivery, plus consumables and vendor-agnostic digital solutions. Q2 2026 revenue fell 13.3% to $675 million with segment EBIT of $(26) million on supply and fulfillment issues, and the business is under a review of strategic options. Led by Jeannette Bankes since May 2025.
Strategic priorities
- D3 growth strategy
- Growth is framed as D3, combining smart devices and drugs, a disease-state focus and digital capabilities, particularly AI, executed through the Heartbeat lean business system.
- New product cycle
- New products such as Photonova Spectra photon-counting CT (shipments from early 2027), Total Body PET, SIGNA Bolt 3T MR and Vivid Pioneer ultrasound are meant to lift growth from the 3%-4% lane to mid-single digits; they are still under 20% of order value.
- Grow Pharmaceutical Diagnostics
- Management says PDx is in "a renaissance window"; the target for the Flyrcado PET tracer is $500 million or more in annual revenue by 2028, and the contrast market is expected to double over the next decade.
- Medium-term margin and growth targets
- Medium-term targets are mid-single-digit organic growth, a high-teens to 20% adjusted EBIT margin and 90% free cash flow conversion; the CEO says the 17-20 margin range remains on track.
- Fix and review Patient Care Solutions
- The first job is to get PCS supply and fulfillment back on track, then decide on options including continued ownership or a sale, with an update expected around February.
- Stabilise China
- China is still modeled down in 2026; the company has localised most in-China-for-China manufacturing, with another 10% to go, and set up a provincial government affairs group to address volume-based procurement.
Latest results
In Q2 2026 total revenues were $5,295 million, up 5.7% reported and 3.5% organic, led by PDx and AIS while PCS fell 13.3%. Organic orders grew 11.1%, book-to-bill was 1.15 times and backlog reached a record $23.9 billion. Adjusted EBIT was $750 million (14.2% margin, down 40 bps) as PCS and inflation in memory chips, oil and freight weighed; Adjusted EPS was $1.13 vs $1.06. IEEPA tariff refunds of $107 million were received in the quarter. Guidance for 2026 was reaffirmed: organic growth of 3.0% to 4.0%, Adjusted EBIT margin of 15.4% to 15.7%, Adjusted EPS of $4.80 to $5.00 and free cash flow of approximately $1.6 billion.
Investments and deals
- Intelerad acquisition
- Acquired March 18, 2026 for approximately $2,293 million in cash; a cloud-first medical imaging software and workflow company with a significant outpatient presence, now part of AIS.
- Nihon Medi-Physics
- The remaining 50% of the Japanese radiopharmaceutical manufacturer was bought for $271 million, making it wholly owned on March 31, 2025.
- AI imaging tuck-ins
- icometrix (AI brain imaging) was acquired for approximately $98 million plus up to $35 million earn-out in November 2025, alongside Spectronic Medical AB.
- R&D and capacity capex
- FY2025 R&D spending was $1,260 million and capex $482 million; capital priorities remain organic investment first, then tuck-in M&A, then buybacks.
Challenges and risks
- Tariffs and cost inflation
- Tariffs cut operating income by approximately $245 million in 2025, and 2026 guidance absorbs approximately $250 million of inflation from memory chips, oil and freight linked partly to the Middle East conflict.
- Patient Care Solutions operations
- PCS revenue fell 13.5% organically in Q2 2026 with negative EBIT, driven by supply of critical components, end-of-life components and fulfillment problems.
- China competition and procurement
- China region revenue fell 4.6% in FY2025 amid local competition and volume-based procurement, which the company models will ultimately be over half of the market.
- Supply chain inputs
- The business depends on helium, iodine and rare earth minerals, and China tightened rare-earth export controls in 2025.
- Debt and pension load
- Total debt was $10,093 million at June 30, 2026, and pension plans carry a total funded deficit of $4,365 million.
What leadership says
“We delivered record orders and backlog in the second quarter, with orders growth across every segment, demonstrating strong commercial execution, including the adoption of new products.”
“while we are focused on returning the business to growth and profitability, we are reviewing strategic options to maximize its long-term value.”
“this is the best lineup GE HealthCare has ever had, period.”
“we're increasingly confident in the $500 million+ by 2028.”
Where a supplier can help
- Component supply and manufacturing for PCS
- Tied to the Patient Care Solutions challenge: suppliers of critical electronic components, redesign of end-of-life parts or contract manufacturing can address the supply and fulfillment issues behind the decline.
- Logistics and input-cost mitigation
- Tied to the tariffs and inflation challenge: freight optimisation, alternative sourcing of memory chips and rare earths, and trade-compliance services fit an inflation load of approximately $250 million.
- Radiopharmacy delivery and workflow
- Tied to the PDx growth priority: Flyrcado adoption depends on radiopharmacy delivery reliability and clinic workflow, so specialised logistics and scheduling tools are relevant.
- Software and AI integration
- Tied to the D3 strategy and the Intelerad acquisition: cloud infrastructure, data integration and AI tooling partners can support imaging software and internal productivity work with agents.
- Local sourcing in China
- Tied to the China priority: local suppliers and manufacturing partners can help complete the remaining localisation needed to compete under volume-based procurement.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like GE HealthCare?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Form 10-K for fiscal year 2025
- GE HealthCare Technologies Inc. (Chicago; Nasdaq: GEHC), spun off from General Electric on January 3, 2023, sells medical devices, consumables, services and AI-enabled cloud and software to hospitals, health systems and researchers in over 160 countries, with approximately 54,000 colleagues, 9,700 sales professionals and 8,900 field service engineers.
- FY2025 total revenues $20,625 million, up 4.8% reported and 3.5% organic; products $13,661 million, services $6,964 million. Operating income $2,763 million; net income attributable $2,084 million; Adjusted EBIT $3,155 million (15.3% margin, down 100 bps); diluted EPS $4.55, Adjusted EPS $4.59; free cash flow $1,505 million.
- Four segments in FY2025: Imaging ($9,245 million, segment EBIT margin 9.6%), Advanced Visualization Solutions ($5,354 million, 22.0%), Patient Care Solutions ($3,086 million, 6.8%, revenue down 1.2%) and Pharmaceutical Diagnostics ($2,900 million, 30.1%, up 15.6%).
- Regions: USCAN $9,531 million (+6.1%), EMEA $5,425 million (+7.4%), China region $2,251 million (-4.6%), Rest of World $3,418 million (+4.2%). China faces local competition and Volume Based Procurement.
- Tariffs cut operating income by approximately $245 million and cash flows by approximately $285 million in 2025; mitigation is not expected to offset them fully.
- Remaining performance obligations $15,729 million at year-end (services $10,728 million); contract liabilities $2,899 million.
- M&A: remaining 50% of Nihon Medi-Physics (radiopharmaceuticals, Japan) bought for $271 million; icometrix (AI brain imaging) for approximately $98 million plus up to $35 million earn-out; agreement to buy Intelerad (imaging software, outpatient) for $2,300 million in cash.
- Balance sheet: total debt $10,003 million, $2,750 million of new notes issued in 2025; $1,000 million buyback authorized April 2025 ($200 million used); quarterly dividend $0.035.
- Competitors named: Siemens Healthineers, Philips Healthcare, United Imaging, Mindray and Canon; in PDx Bayer, Bracco, Guerbet and Curium.
- Main risks: competition, tariffs and geopolitics, payer cost control (including China's volume-based procurement), execution of AI/cloud strategy, supply chain (helium, iodine, rare earths), regulation, $10,003 million of debt and large pension liabilities.
- Form 10-Q for the quarter ended June 30, 2026
- Q2 2026 total revenues $5,295 million, up 5.7% reported and 3.5% organic; H1 2026 $10,425 million, up 6.6% (organic 3.2%).
- New segment structure from Q2 2026: Imaging and AVS combined into Advanced Imaging Solutions (AIS) to give three reportable segments, AIS, PDx and PCS; history recast.
- AIS Q2 revenue $3,771 million (+7.9%, organic +5.0%), segment EBIT $525 million (13.9%); Radiology $2,388 million, Procedural Guidance $715 million, Specialized Ultrasound $668 million.
- PDx Q2 revenue $843 million (+15.6%, organic +14.6%), EBIT $250 million (29.6%), on volume and price in contrast media and radiopharmaceuticals.
- PCS Q2 revenue $675 million (-13.3%), segment EBIT $(26) million, because of operational and fulfillment challenges.
- Q2 operating income $739 million; net income attributable $561 million; Adjusted EBIT $750 million (14.2%); Adjusted EPS $1.13 vs $1.06. H1 free cash flow $180 million vs $106 million.
- Intelerad acquired March 18, 2026 for approximately $2,293 million in cash, included in AIS.
- IEEPA tariff refunds: $107 million received and a $38 million receivable; pre-tax benefits of $106 million (2025 tariffs) and $23 million (2026 tariffs) in Q2. Tariffs still cut Q2 operating income by $68 million before refunds.
- RPO $16,118 million at June 30, 2026; total debt $10,093 million; cash $2,105 million; $300 million of buybacks in H1.
- Middle East conflict, memory chips, freight and oil-linked costs raised costs in Q2; China competition and volume-based procurement remain watch points.
- GE HealthCare reports second quarter 2026 financial results (earnings release)
- Q2 2026 revenue $5.3 billion, +5.7% reported, organic +3.5%, led by PDx and AIS; PCS "continued to be challenged".
- Record organic orders growth of 11.1% (vs 3.4% a year earlier), book-to-bill 1.15 times, backlog $23.9 billion.
- Adjusted EBIT margin 14.2% (down 40 bps) hurt by PCS and inflation in memory chips, oil and freight; diluted EPS $1.24 (+16.5%), Adjusted EPS $1.13 (+6.6%).
- Segment EBIT margins: AIS 13.9% (+90 bps), PDx 29.6% (+30 bps), PCS (3.8)% (down 1,150 bps).
- CEO Peter Arduini: PCS is under a review of strategic options "to maximize its long-term value".
- 2026 guidance reaffirmed: organic growth 3.0% to 4.0%, Adjusted EBIT margin 15.4% to 15.7%, Adjusted EPS $4.80 to $5.00, free cash flow approximately $1.6 billion; approximately $250 million of inflation from memory chips, oil and freight assumed.
- Q2 buyback of 3.3 million shares for $200 million; $500 million left in the authorization; dividend $0.035 per share.
- Commercial highlights: Catholic Health partnership on Long Island, theranostics collaborations with Mayo Clinic and University Hospital Essen, FDA clearance for MIM Contour ProtégéAI+ 2.0.
- GE HealthCare Q2 2026 earnings call transcript
- Peter Arduini (CEO) called Q2 2026 orders (+11%), backlog growth ($2.6 billion year on year) and book-to-bill (1.15x) record levels, with demand healthy in all 3 segments and no one-time items; about 6 enterprise accounts contributed.
- Strategy: D3 (smart devices and drugs, a disease-state focus, digital/AI) plus the Heartbeat lean business system; "AI inside" to grow with lower G&A.
- PCS: revenue -13.5% organic and negative EBIT on supply and fulfillment issues; a review of options "including continued ownership, a sale and other value-enhancing transactions" is under way.
- PDx: organic +14.6%, EBIT margin 29.6%; Flyrcado reached 545 doses in the week ending July 24 (about 40% above April); target of $500 million or more annual revenue by 2028 reaffirmed; contrast demand "close to outpacing total market supply".
- New products: Photonova Spectra photon-counting CT (CE marking expected H2 2026), Vivid Pioneer ultrasound with higher gross margin, SIGNA Bolt 3T MR; new products are still under 20% of order value.
- Catholic Health (New York) signed an approximately $500 million agreement for equipment, service and process expertise.
- Guidance kept: 3% to 4% organic growth, 15.4% to 15.7% Adjusted EBIT margin, Adjusted EPS $4.80 to $5; medium-term targets reaffirmed.
- CFO Jay Saccaro is leaving; George Newcomb is interim CFO. China: still assumes a year-over-year decline in 2026.
- Wells Fargo 21st Annual Healthcare Conference fireside chat
- Peter Arduini (CEO) at the Wells Fargo Healthcare Conference, September 9, 2026, with interim CFO George Newcomb.
- Q2 orders growth over 11% was all equipment; hospitals show no pullback in capital spending; nearly 80% of Q3 revenue was committed entering the quarter.
- PCS review: first fix the business (supply, end-of-life components), then decide whether all parts belong together or "better someplace else"; an update is expected around February.
- China is stabilizing but still expected slightly down in 2026; VBP may exceed half of the market; local sourcing is key.
- PDx is in "a renaissance window"; contrast demand and supply "just matching up"; LRP of high single-digit growth is being outperformed. Flyrcado $500 million in 2028 target reaffirmed.
- Photonova Spectra has CE mark and 510(k); shipments ramp from early 2027. MR SIGNA Bolt is "picking up share for the first time in quite some time"; "this is the best lineup GE HealthCare has ever had" in vascular.
- Medium-term 17-20% margin target is still on track despite almost a couple of hundred basis points of headwinds; new CFO Bill Grogan joins the following week.
- Capital allocation: internal investment first, tuck-in M&A like Intelerad (growing high single digits, margins in the 30s), selective buybacks.
- Jefferies Global Healthcare Conference 2026 fireside chat
- Jay Saccaro (then VP and CFO) at the Jefferies Global Healthcare Conference, June 3, 2026.
- Q1 2026: two-year orders growth of 11%, book-to-bill 1.07x, record backlog of $21.8 billion, revenue +2.9%, mostly from existing products.
- Guidance was cut because of about $250 million of inflation (Middle East conflict about $150 million for logistics and rare earths, plus memory chips); a $0.15 reduction at both ends of the range, with buffers built in.
- Price lags cost because orders in the book carry price risk; much larger price impact expected next year.
- New products (photon-counting CT, Total Body PET, next-gen SPECT, MR with Freelium, Vivid Pioneer, Allia Moveo) are meant to lift growth from the 3%-4% lane to mid-single digits; photon-counting pipeline over $100 million.
- Tariffs: about $250 million net impact last year ($500 million gross before mitigation).
- Flyrcado: $25 million run rate in Q1, $50 million annual run rate in Q2, customer base up 50% since the start of the year; confidence in $500 million+ by 2028.
- China modeled down in 2026 under new leader Will Song; capital allocation favours R&D, then deals where GE HealthCare is one of one or two buyers (Intelerad), and buybacks ($100 million at $70 in Q1).
Questions about GE HealthCare
What does GE HealthCare do?
GE HealthCare sells medical imaging and ultrasound systems, patient monitoring and anesthesia equipment, contrast media and radiopharmaceuticals, services and AI-enabled software to hospitals, health systems and researchers in over 160 countries.
What is GE HealthCare's revenue?
Total revenues were $20,625 million in FY2025, up 4.8% reported. Q2 2026 revenues were $5,295 million, up 5.7%.
How many employees does GE HealthCare have?
Approximately 54,000 colleagues, including about 9,700 sales professionals and 8,900 field service engineers.
Who leads GE HealthCare?
Peter Arduini has been President and CEO since the spin-off. CFO Jay Saccaro left in 2026; George Newcomb served as interim CFO and new CFO Bill Grogan was due to join in mid-September 2026.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)